Search Within

Solid Tumor Oncology Division

Formats
  1. Journal Article (10944)
  2. Meeting Abstract (9499)
  3. Review (562)
  4. Book Section (417)
  5. Editorial (337)
  6. Guidelines (159)
  7. Correspondence (119)
  8. Conference Paper (107)
  9. Research Letter (62)
  10. Miscellaneous (54)
  11. Book Whole (27)
Groups
  1. Department of Medicine (22263)
  2. GSK Faculty (5931)
  3. Genitourinary Oncology Service (5656)
  4. Survivorship Research (5232)
  5. Gastrointestinal Oncology Service (4697)
  6. Breast Medicine Service (4159)

More Groups

People
  1. Robert Motzer (1248)
  2. Howard Scher (1131)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (872)
  6. Leonard Saltz (792)

More People

Years
  1. 2025 (664)
  2. 2024 (1388)
  3. 2023 (1381)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1536)

More Years

Publications
  1. Journal of Clinical Oncology (5290)
  2. Annals of Oncology (1297)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (776)
  5. Journal of Thoracic Oncology (534)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5583)
  2. Elsevier Inc. (2665)
  3. American Association for Cancer Research (2327)
  4. Oxford University Press (1819)
  5. Nature Publishing Group (1044)
  6. Springer (983)

More Publishers

Results (22287)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2-early breast cancer (EBC) treated with endocrine therapy (ET) in the US
    Meeting Abstract

    Razavi, P.; Ahmed, M.; Roush, A.; Parikh, R.; Hitchens, A.; Shen, S.; Safonov, A.; Jhaveri, K. L.; Robson, M. E.; Peacock, N. W.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy (SLL) when administered in combination with bevacizumab (BEV) and neoadjuvant chemotherapy (NACT) in patients newly diagnosed with advanced epithelial ovarian cancer (EOC)
    Meeting Abstract

    Jazaeri, A. A.; Grisham, R. N.; Gaillard, S.; How, J. A.; Hazard, S.; Musso, L.; Kyi, C.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • First-line treatment preferences for advanced melanoma among oncologists and patients in the US: A discrete choice experiment
    Meeting Abstract

    Postow, M. A.; Burgos, G.; DeCongelio, M.; Palaia, J.; Ejzykowicz, F.; Patel, D.; Rosenblatt, L.; Modi, K.; Pittman, Z.; Honomichl, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Immune-related adverse event prediction and influential factor identification
    Meeting Abstract

    Zhang, Y.; Lev-Ari, S.; Shah, N. J.; Gupta, S.; Zaemes, J. P.; Alaoui, A.; McGarvey, P.; Atkins, M. B.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • TBCRC 058: A randomized phase II study of enzalutamide, enzalutamide with mifepristone, and treatment of physician's choice in patients with androgen receptor-positive metastatic triple-negative or estrogen receptor-low breast cancer (NCT06099769)
    Meeting Abstract

    Traina, T. A.; Chen, Y.; Khoury, K.; Rugo, H. S.; Mayer, E. L.; Carey, L. A.; Melisko, M. E.; Syldor, A.; Friedman, C.; Savoie, J.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Updated quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of nivolumab plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for advanced gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma (GC/GEJC/EAC): 4-year (yr) follow-up from CheckMate 649 (CM 649)
    Meeting Abstract

    Lin, D.; Quan, W.; Garretson, M.; Chirikov, V.; Chen, C.; Singh, P.; Davis, C.; Sugarman, R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Glucagon-like peptide-1 (GLP-1) agonist use and weight change among patients with breast cancer
    Meeting Abstract

    Shen, S.; Liu, B.; Fanti, C.; Bromberg, M.; Chen, Y.; Chang, C.; Iyengar, N. M.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Cancer care service use intensity in Medicare Advantage versus traditional Medicare
    Meeting Abstract

    Mitchell, A. P.; Kalidindi, Y.; Feldman, R.; Carlin, C.; Song, G.; Jung, J.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Real world outcomes of sequential ADC therapy in metastatic breast cancer: Patients treated with sacituzumab govitecan and trastuzumab deruxtecan
    Meeting Abstract

    Mai, N.; Klar, M.; Ferraro, E.; Bromberg, M.; Chen, Y.; Razavi, P.; Modi, S.; Chandarlapaty, S.; Walsh, E. M.; Drago, J. Z.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma
    Meeting Abstract

    Doshi, S. D.; Dizman, N.; Knezevic, A.; Touma, A.; Alaghehbandan, R.; Ged, Y.; Ornstein, M. C.; Hahn, A. W.; Msaouel, P.; Voss, M. H.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save